Rhythm Pharmaceuticals Inc (STU:1RV)
€ 38.705 0.845 (2.23%) Market Cap: 2.43 Bil Enterprise Value: 2.24 Bil PE Ratio: 0 PB Ratio: 41.42 GF Score: 52/100

Rhythm Pharmaceuticals, Inc. - Special Call Transcript

Nov 27, 2020 / 02:30PM GMT
Release Date Price: €24 (+20.60%)
Operator

Good morning, ladies and gentlemen, and welcome to the Rhythm Pharmaceuticals Conference Call to discuss the FDA approval of IMCIVREE. (Operator Instructions) As a reminder, this conference might be recorded.

I would now like to turn the call over to your host, Mr. David Connolly, Investor Relations and Corporate Communications. Sir?

David Connolly
Rhythm Pharmaceuticals, Inc. - Head of IR & Corporate Communications

Thank you, and thank you to everyone for joining us this morning to discuss the FDA's approval of IMCIVREE, setmelanotide, for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency.

Please note the press release issued earlier today and presentation we're using for this conference call are available online on the Investors & Media section of our website, rhythmtx.com.

Before we begin -- turning to Slide 2. Before we begin, I'd like to remind everybody that there will be forward-looking statements made on this call. Actual events or results could differ materially from those

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot